






































In-vivo administration of histone deacetylase
inhibitors does not impair natural killer cell function
in HIVR individuals
Carolina Garridoa,b, Martin Tolstrupe, Ole S. Søgaarde,
Thomas A. Rasmussene, Brigitte Allarda,b, Natalia Soriano-Sarabiaa,b,
Nancie M. Archina,b and David M. Margolisa,b,c,d
Objective: Histone deacetylase inhibitors (HDACi) have proven to induce HIV-RNA
and antigen expression in resting CD4þ T cells of antiretroviral therapy (ART)-treated
HIV-infected individuals. However, to achieve viral eradication, immune clearance
must follow latency reversal, and thus it is essential to understand the impact of latency
reversal agents on immune function.
Design: Here we evaluate the impact of in-vivo administration of vorinostat (VOR) and
panobinostat (PNB) during clinical trials on natural killer (NK) cell function and phenotype.
Methods: Cryopreserved peripheral blood mononuclear cells from HIV-positive parti-
cipants receiving VOR (NCT01319383) or PNB (NCT01680094) were selected to assess
the impact of the drugs on cell composition, activation, NK cell phenotype (CD16,
NKG2D, NKp30, NKp46 and DNAM-1), cytotoxic activity (CD107a), and interferon
(IFN)-g production.
Results: No impairment of NK cell function was observed during treatment with either
VOR or PNB. An increase in the frequency of CD3CD56þ NK cells was consistently
observed. Interestingly, after VOR administration, NK cells increased expression of
NKp46 and CD16, and showed improved degranulation and IFN-g production capac-
ity. Moreover, taking together VOR and PNB samples, HIV DNA levels in CD4þ cells
were negatively correlated with NK cell frequency and NK cell expression of CD16.
Conclusions: In-vivo treatment with HDACi does not have measurable negative effects
on NK cell function, with some evidence of improved function in vitro. These results
have important implications for potential combinatorial approaches to target HIV
reservoirs, suggesting that the use of HDACis as a latency reversal agent could be
paired with interventions to enhance NK cell activity or recruitment.
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Introduction
Research strategies geared towards curing persistent HIV
infection have entered clinical testing [1]. The most
advanced of these approaches involves the administration
of compounds known as latency-reversing agents (LRAs)
to induce HIV gene transcription, thus allowing
expression of latent virus within infected cells. Histone
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deacetylase inhibitors (HDACi) are drugs employed to 
treat certain cancers that have also been demonstrated to 
reactivate HIV from latency [2–6]. Vorinostat (SAHA, 
VOR) was the first drug from this family to be tested in 
the clinic as an LRA [7–10]. Following VOR, two other 
HDACi – panobinostat (PNB) [11] and romidepsin 
(RMD) [12,13] – also entered clinical study. All three 
drugs increased cell-associated HIV RNA (ca-RNA) in 
CD4þ T cells from antiretroviral therapy (ART)-
suppressed individuals, but failed to reduce the frequency 
of latently infected cells. Therefore, approaches to 
enhance immune responses following latency reversal 
are required to eliminate infected cells.
Initial efforts towards enhancement of immune responses 
were focused on HIV-specific CD8þ T cells [14–18], either 
through ex-vivo expansion or vaccination strategies. In-vitro 
studies have suggested that some LRAs might have a negative 
impact on the viability or function of CD8þ T cells [19–21], 
although this has not been confirmed in vivo [14]. More 
recently, there has been a growing interest in the exploration 
of natural killer (NK) cells as cytotoxic effectors in HIV-
eradication strategies, as they have shown potential to be 
clinically exploited for HIV clearance [22]. Critical to those 
endeavors is the assessment of the effect of LRAs on NK cell 
function. To that end, we previously performed a study 
evaluating the effect of ex-vivo LRA exposure on NK cells 
[23]. In that ex-vivo study, we demonstrated that different 
compounds cause diverse effects on NK cells, with 
differences observed even within a given class of compounds. 
We observed that although VOR did not negatively affect 
NK cell function, PNB and RMD induced undesirable 
alterations [23]. However, given that the in-vivo milieu 
cannot be fully replicated by ex-vivo modeling, assessing the 
impact  of  in-vivo exposure to LRAs on NK cell is extremely  
important. In the present study, we report a direct assessment 
of NK cell function in cells obtained from HIVþ participants 
receiving VOR or PNB in clinical studies.
Methods
Study samples
Viably frozen peripheral blood mononuclear cells
(PBMCs) were derived from participants included in
two clinical trials involving two different HDAC
inhibitors: VOR and PNB. Basic characteristics of the
clinical trials performed with HDACi in the context of
HIV are summarized in Table 1.
The VOR samples were derived from five participants
enrolled in the clinical trial NCT01319383 [24], which
evaluated the effect of 22 cyclical doses of VOR over a
period of 12–16 weeks. Briefly, 400 mg of VOR was
administered daily Monday to Wednesday for 4 weeks, for
a total of 11 doses. After a rest period, participants
received another 4 weeks of VOR doses Monday to
Wednesday to reach a total of 22 doses. PBMCs from the
participants were obtained by leukapheresis at baseline,
after the first 4-week cycle (on the morning after the 11th
dose, ‘11 VOR-doses’) and at the end of the study (on the
morning after the 22nd dose, ‘22 VOR-doses’), and
viably frozen until use.
The PNB specimens were derived from the CLEAR
study (NCT01680094) [11], in which 15 participants
were administered 20 mg PNB three times per week
(Monday, Wednesday, and Friday) every other week for 8
weeks. PBMCs were obtained 8 h after a PNB dose. In
the present study, we included samples from five of these
participants, with one sample before treatment (‘pre-
PNB’), after 4 doses (‘4 doses’), after 10 doses (‘10 doses’),
and 4 weeks after completing treatment (‘follow-up’).
Participants included in both trials were virally suppressed
(<50 HIV RNA copies/ml) on ART for at least 2 years,
and had CD4þ cell counts above 470 cells/ml.
Cell processing
Viably frozen PBMCs from each participant at different
time points were thawed simultaneously and rested on
culture for 24 h. An aliquot was used to analyze the
frequency of each cell population (i.e. CD4þ, CD8þ, and
NK cells), and assess proliferation and activation markers.
A second aliquot was used to isolate NK cells (EasySep
Human NK Cell negative selection Enrichment Kit,
StemCell Technologies, Vancouver, British Columbia,
Canada) to study expression of activating receptors and
immune function. After isolation, the purity of NK cells
was consistently above 85%.
Table 1. Summary of the clinical trials conducted with HDACi in the context of HIV infection.
Clinical trial # Dose Dosing References
NCT01319383 8 400 mg One dose Archin et al., 2012 [7]
NCT01319383 5 400 mg Three doses/week for 8 weeks Archin et al., 2014 [24]
NCT01365065 20 400 mg One daily for 14 days Elliott et al., 2014 [10]
VOR One dose
NCT01319383 16 400 mg 1þ1 after 48 h Archin et al., 2017 [9]
1þ1 after 72 h
10 doses every 72 hours
PNB NCT01680094 15 20 mg 3 times/week every other week for 8 weeks Rasmussen et al., 2014 [11]
RMD NTC02092116 6 5 mg/m2 1 time/week for 3 weeks (intravenous) Søgaard et al., 2015 [12]
HDACi, histone deacetylase inhibitors; PNB, panobinostat; RMD, romidepsin; VOR, vorinostat
Analysis of cell phenotype
Peripheral blood mononuclear cells were stained with a
panel of monoclonal antibodies to define cell populations.
The antibody panel included CD3-PerCP (clone SK7,
BD Biosciences, San Jose, California, USA), CD4-FITC
(clone RPA-T4; BD Biosciences), CD8-AlexaFluor700
(clone SK1; Biolegend, San Diego, California, USA), and
CD56-PE (clone NCAM16.2; BD Bioscience). Cell
subsets were derived from the singlets gate within the
lymphocyte population, and were classified as NK cells
when they were CD3CD56þ, CD4þ T cells when they
co-expressed CD3þ and CD4þ, and CD8þ T cells when
they were double positive for CD3þ and CD8þ (Fig. 1a).
In addition, proliferation and activation markers were
analyzed using Ki67-PE/Cy7 (Biolegend) and CD69-
APC (clone FN50; Biolegend). Another antibody panel
was designed to examine the expression of NK-activating
receptors on isolated NK cells. This panel included the
following antibodies from Biolegend: CD16-Alexa-
Fluor700 (clone 3G8), NKG2D-APC (clone 1D11),
NKp30-PE (clone P30–15), NKp46-PE/Cy7 (clone
9E2), and DNAM1-FITC (clone 11A8). Briefly, cells
were resuspended in staining buffer and incubated with an
optimized antibody concentration for 20 min on ice in
the dark. Cells were then washed twice, fixed and
analyzed using the Attune NxT Acoustic Focusing
Cytometer (Applied Biosystems, Forster City, California,
USA). Fluorescence minus one controls (FMO) were
used for each antibody combination to set the gates.
Analysis was performed using the FlowJo software v10
(Ashland, Oregon, USA).
Functional assays
The function of NK cells was assessed by measuring
degranulation, through the degranulation marker
CD107a [25], and interferon (IFN)-g production by
intracellular staining. Isolated NK cells were cocultured
with the major histocompatibility complex class I lacking
target cell line K562 at a 1 : 1 effector-to-target ratio,
along with CD107a-PE/Cy7 (clone H4A3, Biolegend)
for 2–4 h, adding the protein transport inhibitor Golgi-
Stop (BD Biosciences) after the first hour. Cells were then
Fig. 1. Frequency of cell populations, proliferation, and activation during HDAC inhibitor treatment. The PBMCs were stained
with a panel of monoclonal antibodies to analyze cell populations and expression of proliferation and activation markers. (a)
Representative plot of cell gating strategy. (b) VOR treatment: the proportion of CD4þ and CD8þ T cells did not change during VOR
treatment, but frequency of NK cells increased after 11 doses of VOR, with increases maintained after 22 doses. Expression of the
proliferation marker Ki67 and the activation marker CD69 decreased during VOR treatment. (c) PNB treatment: CD4þ and CD8þ T
cells remained stable during PNB treatment, but NK cells showed an increase, that was lost after the end of treatment. A decrease in
CD69 was observed during PNB treatment. Each symbol represents cells from a different study participant. Wilcoxon matched-pairs
signed rank test. HDAC, histone deacetylase; PBMCs, peripheral blood mononuclear cells; PNB, panobinostat; VOR, vorinostat.
harvested and stained with CD3-APC/Fire750 (clone
SK7; Biolegend) and CD56-FITC (clone HCD56;
Biolegend). Cells were washed, and after fixation and
permeabilization, intracellular staining with IFN-g-PE
(clone 4SB3; Biolegend) antibody was performed. Cells
were acquired using the Attune NxT Acoustic Focusing
Cytometer, and analysis was performed using the Flowjo
v.10. Cells were gated according to CD3 and CD56
expression to determine the proportion of NK cells
expressing the degranulation marker CD107a and/or
producing IFN-g (Fig. 2a).
Frequency of latent HIV infection
Measurements of the frequency of latent HIV infection
within each participant was determined at the different
time points as described in detail by Archin et al. [24] for
VOR, and Rasmussen et al. [11] for PNB. Briefly,
measurement of the frequency of infection included
quantification of HIV-1 pol DNA copies from resting or
total CD4þ T cells, analyzed by digital droplet PCR
(ddPCR), and quantification of replication-competent
virus using the quantitative viral outgrowth assays
(QVOA), which provides a minimum estimation of
the frequency of replication competent HIV reported as
infectious units per million cells (IUPM).
Ethics statement
All donors provided written informed consent. Studies
were approved by the University of North Carolina
Institutional Review Board for the VOR samples and by
the Danish Research Ethics Committee system for PNB
samples. Specimens used in the study were anonymized.
Statistical analysis
Given the limited sample size, the statistical analysis was
exploratory with no adjustment for multiple testing.
Pretreatment versus post-treatment measurements were
compared with an exact two-sided Wilcoxon signed-rank
test. For each study (VOR and PNB), measurements from
five donors were available. Using a two-sided Wilcoxon
signed-rank test, the smallest obtainable exact P value with
n¼ 5 is P¼ 0.0625. Analysis was performed with
GraphPad Prism v7. The correlation between the different
parameters and the size of the reservoir was assessed by
pooling measurements from pretreatment, mid-treatment,
and post-treatment. A Spearman’s r was calculated, but we
also performed a Kendall tau correlation, because there
were several measures from each participant.
Results
Natural killer cell frequency is increased after in-
vivo administration of HDACi
For VOR, phenotypic analysis on PBMCs was performed
at three time points: before VOR administration
(’pre-VOR’), after 11 doses, and after 22 doses. Levels
of CD4þ and CD8þ T cells remained constant over the
treatment period. However, we observed an increase in
the frequency of NK cells in all donors, who had a mean
of 7.13% NK cells at baseline, 13.9% after 11 doses, and
14.24% after 22 doses (Fig. 1b).
For PNB, analysis was performed in PBMCs at four time
points: pre-PNB, after 4 and 10 doses, and after
completion of treatment (’follow-up’). As with VOR,
there was no change over time in the proportion of CD4þ
or CD8þ T cells, but consistent with VOR, we observed
an increase in the frequency of NK cells during PNB
treatment in all participants (3.6% pre-PNB, 5.6% at visit
6, 5.4% at visit 10 and back to 3.2% in the follow-up
sample; Fig. 1c).
Natural killer cells can be classified into bright and dim
according to CD56 expression. Interestingly, we observed
that CD56dim NK cells proportion increased in all
participants (median of 93.72% before treatment and
96.1% after drug exposure), whereas CD56bright fre-
quency decreased in most of them (median of 5.6 vs.
3.47%).
Expression of the proliferation marker Ki67 and the early
activation marker CD69 were also analyzed in total
PBMCs and within the different cell subsets. Both VOR
and PNB treatment resulted in a decrease of the
expression of CD69, either analyzing the entire cell
population (Fig. 1b, c) or the different cell subsets (data
not shown). Conversely, Ki67 expression pattern differed
after treatment with VOR or PNB. Ki67 expression
significantly decreased after VOR treatment (Fig. 1b),
whereas it remained unchanged after PNB treatment
(Fig. 1c).
In-vivo VOR treatment increases natural killer
cell capacity to degranulate and produce
interferon-g
Natural killer cell degranulation and IFN-g production
potential were evaluated after coculture of isolated NK
cells with the cell line K562. Degranulation was measured
using surface CD107a expression, and IFN-g production
was assessed by intracellular staining. Due to limited
sample availability, NK cell function could only be
assessed in response to K562 cells, but we acknowledge
that additional analysis of NK cell responses such as
antibody-dependent cell cytotoxicity would provide
further evidence of function alterations. Interestingly,
VOR treatment improved both degranulation and IFN-g
production of NK cells after culture with K562 cells
(Fig. 2b). Conversely, we did not find any function
alteration after PNB treatment (Fig. 2c). In addition, we
found a positive correlation between the frequency of NK
cells, and both degranulation and IFN-g production.
Functional markers also correlated positively with the
expression of NKp30, NKp46, NKG2D, and CD16 (data
not shown).
CD16 and NKp46 are up-regulated after
vorinostat treatment
The NK cells express a wide variety of receptors that
enable them to differentiate tumor or infected cells from
healthy cells. These include inhibitory, activating,
adhesion, and cytokine receptors. The balance of these
signals determines whether NK cells become activated or
not [26]. Following NK cell isolation by negative
selection, we analyzed the expression of a selection of
activating receptors on the surface of NK cells. Expression
Fig. 2. Natural killer (NK) cell cytotoxicity and cytokine production. The NK cells were negatively isolated from thawed PBMCs
and cultured with the cell line K562 to measure degranulation through the marker CD107a and IFN-g production by intracellular
staining. (a) Representative plots of cells from one participant. (b) VOR treatment: an increase in both degranulation and IFN-g
production was observed after VOR exposure. (c) PNB treatment: cytotoxic and IFN-g potential remained stable during PNB
treatment. Each symbol represents cells from a different study participant. Wilcoxon matched-pairs signed-rank test. IFN,
interferon; PNB, panobinostat; VOR, vorinostat.
of DNAM-1, NKp30, and NKG2D were not altered by
VOR exposure, but interestingly, NKp46 and CD16
expression were up-regulated to some extent in most
participants (Fig. 3a). Specifically, CD16 up-regulation
occurred exclusively within the CD56dim subset, whereas
it decreased in the CD56bright population. In contrast,
PNB treatment did not seem to impact in the expression
of any receptor (Fig. 3b).
Correlation with the HIV reservoir size
We analyzed whether the different parameters measured
in the present study were correlated with the size of the
reservoir, measured either as total DNA in CD4þ cells or
as IUPMs. Interestingly, after combining all time points
from both VOR and PNB studies, some correlations
were found. There was a negative correlation between the
frequency of NK cells and the copies of DNA/million
CD4þ cells (Spearman’s r¼0.51, P¼ 0.0017, Kendall’s
tau¼0.33, 95% CI 0.57,0.08). Similarly, there was
a negative correlation between CD16 expression in NK
cells and HIV-DNA (Spearman’s r¼0.43, P¼ 0.01,
Kendall’s tau¼3.8, 95% CI 0.72, 0.17), and also a
trend (P¼ 0.09) towards a negative correlation between
NK cell IFN-g production and HIV-DNA content.
Unexpectedly, a positive correlation was observed
between NKG2D expression and HIV-DNA (Spearman’s
r¼ 0.35, P¼ 0.041, Kendall’s tau¼ 0.26, 95% CI 0.08,
0.52) (Fig. 4). No significant correlation was found
between HIV reservoir size measured as IUPM and any of
the analyzed parameters (data not shown).
Discussion
One of the present strategies aimed at eradicating
persistent HIV infection consists of combining LRAs
with approaches to induce robust immune responses
capable of identifying and clearing reactivated cells.
Therefore, it is critical to discern if interventions used for
latency reversal have any impact on the immune function
needed for viral clearance. In the present study, we have
evaluated the effect of in-vivo administration of HDACi
on NK cell function. We have used samples from a clinical
trial involving VOR (NCT01319383), in which five
HIV-1-infected participants were administered 22 cycli-
cal doses of 400 mg VOR over a period of 12 weeks [24],
and a clinical trial involving PNB (NCT01680094) [11],
in which 15 participants received 20 mg PNB three times
a week every other week for 8 weeks. We analyzed the
phenotype and the functionality of the immune cells in
samples obtained before, during, and after clinical
exposure to the drugs, focusing on NK cells.
The main finding of the study is that NK cell immune
function was not impaired in samples from participants
treated with either of the two HDACi. In addition, a
moderate but consistent increase in the frequency of NK
cells during HDACi treatment was observed, contrasting
with stable frequencies of CD4þ and CD8þ T cells.
Unfortunately, whether the observed increase in NK cells
in peripheral blood is due to proliferation or to cellular
redistribution, cannot be concluded from this study.
Interestingly, we observed an enhancement in the
Fig. 3. Expression of activating receptors on natural killer (NK) cells. The NK cells were negatively isolated from thawed PBMCs
and stained with a panel of monoclonal antibodies to analyze the expression of activating receptors. (a) VOR treatment: NKp30,
DNAM-1, and NKG2D expression did not change during treatment, but expression of CD16 and NKp46 was increased to some
extent after VOR administration. (b) PNB treatment: no changes were observed during PNB treatment. Each symbol represents cells
from a different study participant. Wilcoxon matched-pairs signed-rank test. PBMCs, peripheral blood mononuclear cells; PNB,
panobinostat; VOR, vorinostat.
capacity of NK cells to degranulate and produce IFN-g
following in-vivo administration of VOR. This improve-
ment was accompanied by an increase in the expression of
the activating receptors CD16 and NKp46, which, in
addition, were positively correlated with degranulation
and/or production of IFN-g. PNB treatment did not
cause any functional impairment, but no improvement
was observed either. Finally, pooling together the data
from both VOR and PNB studies, we observed an
interesting negative correlation between the copies of
HIV DNA/million CD4þ cells and the frequency of NK
cells, and also with NK cell expression of CD16.
The question of whether HDACi suppress immune
function is still under debate. Concern was initially raised
when Jones et al. [19] reported that HDACi impaired
cytotoxic T-lymphocyte-mediated IFN-g production
and the elimination of HIV-infected cells in vitro.
However, later studies only partially confirmed these
observations [15,20], highlighting the importance of
factors such as specific HDACi classes, drug concentra-
tions, and the length of drug exposure, which could have
acted as confounding players in study outcomes.
This is the first evaluation of NK cell function performed
after in-vivo administration of VOR or PNB. Previous
studies have evaluated the impact of VOR exposure on
NK cell function in vitro or ex vivo. We performed a
comprehensive analysis of the effect of ex-vivo exposure
of different HIV LRAs on NK cell phenotype and
function. In regards to VOR, we did not observe any
major impact on NK cells [23], in agreement with the
present in-vivo results. However, other studies evaluating
in-vitro impact of VOR exposure on NK cell parameters
reported contradictory results. Pace et al. [27] reported
similar results as our group, detecting no impairment of
NK cell function after exposure to VOR, whereas
Ogbomo et al. [28] and Pfeiffer et al. [29] observed a
decrease in NK cytotoxicity. One potential explanation
for these discrepancies is the different concentration and
time of exposure used. In our experiments, and also in
Pace et al.’s study, a concentration of 335 nmol/l was used
over 24 h, to model peak VOR exposures in vivo, as VOR
is cleared in less than 6 h [30]. On the contrary, Ogbomo
et al. used a continuous VOR concentration of 0.5–
1 mmol/l over 96 h, and Pfeiffer et al. 1 mmol/l over 48 h.
Regarding PNB, in our ex-vivo study, we observed that a
PNB exposure consisting of 20 ng/ml during 24 h, which
aimed to mimic physiologic conditions, increased NK
cell death and reduced immune function [23], whereas in
the present in-vivo study, we did not observe such
impairment. Therefore, while in-vitro studies are
undoubtedly of interest, it is obvious that in-vivo
administration of the drug entails more complicated
pharmacodynamics and cellular interactions that might
provide different outcomes.
Studies of NK cell immune function after in-vivo
exposure to HDACi are limited. In the clinical trial using
PNB in HIV-1-infected individuals, Olesen et al. [31].
found a correlation between HIV reservoir decline
during PNB treatment and NK cell frequency, reporting
that the proportions of total and CD56dimCD16þ NK
cells were inversely associated with HIV-1 DNA levels
[31]. In agreement to these results, when we pooled the
data obtained in the VOR and PNB study for sample size
purposes, we observed a negative correlation between
HIV DNA content and the proportion of NK cells
(Fig. 4). However, we failed to detect such a correlation
with the size of the replication competent reservoir
(estimated as IUPMs by viral outgrowth assay), but this
can be due to a reduced sample size, because IUPM data
were available only in a subset of samples. In the present
study, in addition to the correlation between HIV DNA
and NK cell frequency, we observed an interesting
negative correlation between HIV DNA and CD16
expression, and also a trend towards reduced HIV DNA
content and NK cell IFN-g production. Interestingly, this
observation has been reported previously [32], and thus,
the hypothesis that enhanced NK cell phenotype and
function might have an impact in the HIV reservoir size
deserves further investigation.
In summary, in-vivo administration of HDACi does not
negatively impact NK cell function. Furthermore, we
observed an increase in NK cell frequency during HDACi
Fig. 4. Correlation with the HIV reservoir size. Size of the HIV reservoir was measured as total DNA per million CD4þ cells or as
IUPMs after quantitative outgrowth assay. HIV DNA correlated negatively with NK cell frequency, CD16 expression, and IFN-g
production, whereas it correlated positively with NKG2D expression. Circles correspond to samples from the VOR study and
squares to the PNB study. Grey represent samples before HDACi treatment, black during treatment, and crossed black after
treatment. HDACi, histone deacetylase inhibitors; IUPM, infectious units per million cells.
treatment, and interestingly, VOR exposure improved
cytotoxicity potential and capacity of NK cells to produce
IFN-g, and also the expression of the activating receptor
NKp46. Finally, there was a negative correlation between
the size of the HIV reservoir measured as HIV DNA in
CD4þ T cells, and the frequency of NK cells and
expression of CD16. These results have important
implications in light of HIV-eradication strategies
combining latency reversal with immune enhancement
interventions.
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